Crossbeta gains new ceo and funding

Dutch biotech to advance technology in several therapeutic areas

Crossbeta Biosciences, based in Utrecht in The Netherlands has appointed Guus Scheefhals as chief executive.

Scheefhals has joined the biotech firm from Avantium, where he held several managerial positions, most recently as chief operating officer of the pharma business unit. Prior to Avantium, he held commercial positions at DSM Biologics, Analytico and NPBI, which is now part of Fresenius.

Scheefhals replaces Johan Renes, who steps down after being with the company from the start and for the past two years as part-time ceo.

Crossbeta has recently won funding of €2m, which will be used to advance the firm’s technology in several therapeutic areas and to establish a stronger position for co-development programmes and commercialisation partnerships.

You may also like

Research & Development

Probiodrug and Crossbeta Biosciences enter into a partnership in the field of Alzheimer’s disease biomarkers

Licensing and supply agreement is based on Crossbeta’s proprietary technology and supports Probiodrug’s biomarker development activities
Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development

Shimadzu’s Design Craftech

Fusing traditional Kyoto craft techniques with industrial production
Subscribe now